3. Recipients who are less than 30 days post qualifying transplant. [Note: Under extreme circumstances due to timing issues associated with logistics, patients may be enrolled, i.e.receive first dose of study drug, up to Day 32 post-transplant. Sites must first contact the Chimerix Medical Monitor to receive permission for FDD to be Days 31 or 32 post-transplant.]